Insmed Incorporated Files Shelf Registration Statement

Insmed Incorporated (Nasdaq: INSM) has filed a shelfregistration statement with the Securities and Exchange Commission(SEC) that when declared effective by the SEC would allow Insmed tosell up to $75,000,000 of its common stock, preferred stock orwarrants for common or preferred stock. Insmed may sell thesesecurities in one or more separate offerings in amounts, at prices andon terms to be determined at the time of such offer or offerings. Thisshelf registration statement is intended to give Insmed flexibility totake advantage of financing opportunities when and if deemedappropriate by the Company. Insmed expects to use the proceeds fromany of these offerings for general corporate purposes, includingexpanding commercial and marketing efforts; increasing workingcapital; funding capital and clinical development expenditures;acquiring new products or technologies; and making other investments.

A registration statement relating to these securities has beenfiled with the Securities and Exchange Commission but has not yetbecome effective. These securities may not be sold nor may offers tobuy be accepted prior to the time the registration statement becomeseffective. This press release shall not constitute an offer to sell,or the solicitation of, an offer to buy nor shall there be any sale ofthese securities in any state or jurisdiction in which such offer,solicitation or sale would be unlawful prior to registration orqualification under the securities laws of any such state orjurisdiction.

About Insmed Incorporated

Insmed is a biopharmaceutical company focused on the developmentand commercialization of drug candidates for the treatment ofmetabolic diseases and endocrine disorders with unmet medical needs.For more information, please visit www.insmed.com.

Statements included within this press release, which are nothistorical in nature, constitute forward-looking statements forpurposes of the safe harbor provided by the Private SecuritiesLitigation Reform Act of 1995, including any statement regardingInsmed's ability to offer its securities or the expected use of theproceeds from such offer or offering. These statements represent,among other things, the expectations, beliefs, plans and objectives ofmanagement and/or assumptions underlying or judgments concerningmatters discussed in this document. The inclusion of forward-lookingstatements should not be regarded as a representation by Insmedregarding its ability to offer its securities pursuant to the shelfregistration statement or regarding the timing of any such offer orofferings. We do not plan to update these forward-looking statements.You should be aware that our actual results could differ materiallyfrom those contained in the forward-looking statements due to a numberof risks affecting our business that include, but are not limited to,our planned clinical trial design, our regulatory and businessstrategies, plans and objectives of management and growthopportunities for existing or proposed products. Such forward-lookingstatements are subject to numerous risks and uncertainties, includingrisks that product candidates may fail in the clinic or may not besuccessfully marketed or manufactured, the company may lack financialresources to complete development of product candidates, the FDA mayinterpret the results of our studies differently than we have,competing products may be more successful, demand for newpharmaceutical products may decrease, the biopharmaceutical industrymay experience negative market trends and other risks detailed fromtime to time in the company's filings with the Securities and ExchangeCommission. As a result of these and other risks and uncertainties,actual results may differ materially from those described in thispress release. For further information with respect to factors thatcould cause actual results to differ from expectations, reference ismade to reports filed by the Company with the Securities and ExchangeCommission under the Securities Exchange Act of 1934, as amended. Theforward-looking statements made in this release are made only as ofthe date hereof and Insmed disclaims any intention or responsibilityfor updating predictions or financial guidance contained in thisrelease.